American Healthcare REIT, Inc 8-K, filed Mar 19, 2021
American Healthcare REIT, Inc. (AHR)
8-K
2021-03-19
For: 2021-03-18
View Original
Added on
April 10, 2026
About this 8-K
American Healthcare REIT, Inc filed this 8-K on March 19, 2021, reporting on events of March 18, 2021.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 18, 2021
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: (949 ) 270-9200
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| None | None | None | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01 Regulation FD Disclosure.
On March 19, 2021, Griffin-American Healthcare REIT IV, Inc. (the “Company”) issued a letter to its stockholders announcing important updates, including the formation in October 2020 of a special committee of the Company’s board of directors (the “Board”) to investigate and analyze strategic alternatives that may be available to the Company, the Board’s subsequent decision in March 2021 to suspend the Company’s Distribution Reinvestment Plan (“DRIP”) and Share Repurchase Plan (“SRP”) in light of developments in the strategic review process, and an updated estimated per share net asset value (“NAV”) of the Company’s Class T and Class I common stock of $9.22, as discussed in greater detail in Item 8.01 of this Current Report on Form 8-K below. A copy of the letter to stockholders, which is hereby incorporated into this filing in its entirety, is attached to this Current Report on Form 8-K as Exhibit 99.1.
The information furnished under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the “Securities Act”), unless it is specifically incorporated by reference therein.
Item 8.01 Other Events.
FORMATION OF SPECIAL COMMITTEE AND TEMPORARY SUSPENSION OF DRIP AND SRP
In October 2020, the Board established a special committee of the Board (the “Special Committee”) consisting of all of the Company’s independent directors, Dianne Hurley, Brian J. Flornes and Wilbur H. Smith III, to investigate and analyze strategic alternatives that may be available to the Company, including but not limited to, the sale of the Company’s assets, a listing of the Company’s shares on a national securities exchange, or a merger with another entity, including a merger with another unlisted entity that we expect would enhance the value of the Company. Truist Securities is acting as a financial advisor to the Special Committee and is assisting the Special Committee in the process of reviewing strategic alternatives. There can be no assurance that this strategic alternative review process will result in a transaction being pursued, or if pursued, that any such transaction would ultimately be consummated.
In connection with the strategic alternative review process and in order to facilitate a strategic transaction, on March 18, 2021, the Board authorized the suspension of the DRIP, effective as of April 1, 2021. As a consequence of the suspension of the DRIP, beginning with the April 2021 distributions, which will be payable on or about May 1, 2021, there will be no further issuances of shares of the Company’s common stock pursuant to the DRIP, unless and until the Board reinstates the DRIP, and stockholders who are current participants in the DRIP will receive cash distributions instead. For individual retirement accounts and other qualified accounts, distributions will be remitted to the stockholder’s custodian of record. There can be no guarantee that the DRIP will be reinstated by the Board.
Also in connection with the strategic alternative review process and in order to facilitate a strategic transaction, on March 18, 2021, the Board approved the suspension of the SRP with respect to all repurchase requests received by the Company after February 28, 2021, including repurchases resulting from the death or qualifying disability of stockholders. Any share repurchase requests received by the Company pursuant to the SRP that are not processed due to the suspension shall be considered outstanding share repurchase requests, unless withdrawn by the requesting stockholder. There can be no guarantee that the SRP will be reinstated by the Board.
APRIL 2021 DISTRIBUTIONS
The Board authorized a daily distribution to the Company’s Class T and Class I stockholders of record as of the close of business on each day of the period commencing on April 1, 2021 and ending on April 30, 2021. The daily distributions will be calculated based on 365 days in the calendar year and will be equal to $0.001095890 per share of the Company’s common stock, which is equal to an annualized distribution rate of $0.40 per share. As discussed in greater detail above, on March 18, 2021 the Board approved the suspension of the Company’s DRIP, and therefore, distributions for the month of April 2021 will be paid in cash to all stockholders. The distributions will be aggregated and paid in cash on a monthly basis, in May 2021, only from legally available funds.
ESTIMATED PER SHARE NAV
On March 18, 2021, the Board, at the recommendation of the Audit Committee of the Board (the “Committee”), which Committee is comprised solely of independent directors, unanimously approved and established an updated estimated per share NAV of the Company’s Class T and Class I common stock of $9.22. The updated estimated per share NAV is based on the estimated value of the Company’s assets less the estimated value of the Company’s liabilities, divided by the number of shares of Class T and Class I common stock outstanding on a fully diluted basis, calculated as of September 30, 2020 (the “Valuation Date”). The Company is providing this updated estimated per share NAV to assist broker-dealers in connection with their obligations under Financial Industry
Regulatory Authority (“FINRA”) Rule 2231, with respect to customer account statements. This valuation was performed in accordance with the methodology provided in Practice Guideline 2013-01, Valuations of Publicly Registered Non-Listed REITs, issued by the Institute for Portfolio Alternatives (“IPA”) in April 2013 (the “IPA Valuation Guidelines”), in addition to guidance from the United States Securities and Exchange Commission (“SEC”). The Company continues to monitor the impact the coronavirus (“COVID-19”) pandemic may have on the Company’s business, residents, tenants and operating partners, and on the United States and global economies. Therefore, although the Company intends to publish an updated estimated per share NAV on an annual basis, the Company may be required to reevaluate the updated estimated per share NAV sooner if the COVID-19 pandemic has a material adverse impact on the Company, its residents, tenants, operators or assets. The Board previously determined an estimated per share NAV of the Company’s common stock of $9.54 calculated as of December 31, 2019.
Background
The Committee, pursuant to authority delegated by the Board, was responsible for the oversight of the valuation process, including the review and approval of the valuation process and methodology used to determine the updated estimated per share NAV of the Company’s common stock, the consistency of the valuation and appraisal methodologies with real estate industry standards and practices and the reasonableness of the assumptions used in the valuations and appraisals.
In determining the updated estimated per share NAV, the Committee and the Board considered information and analysis, including valuation materials that were provided by Jones Lang LaSalle Securities, LLC (“JLLS”), an independent FINRA registered broker-dealer firm that specializes in providing valuations, capital markets, corporate finance and real estate financial services, and information from Griffin-American Healthcare REIT IV Advisor, LLC, the Company’s external advisor (the “Advisor”), including the Advisor’s current views on the continued material adverse impact of the COVID-19 pandemic on the Company, its residents, tenants, operators and assets. The engagement of JLLS was approved by the Committee. JLLS engaged JLL Valuation & Advisory Services, LLC (“JLL Valuation & Advisory Services”), an affiliate of JLLS that conducts appraisals and valuations of real properties, to perform cash flow projections and unlevered, ten-year discounted cash flow (“DCF”) analyses from restricted-use appraisals for each of the Company’s operating assets as of September 30, 2020. JLLS prepared a valuation report (the “Valuation Report”), summarizing key information and assumptions and providing an appraised value on 87 assets, consisting of medical office, senior housing and skilled nursing properties (the “Appraised Properties”) wholly and partially owned by the Company as of September 30, 2020, reduced by JLLS’s valuation of the interest held by the Company’s joint venture partners, unaffiliated third parties, with respect to the Central Florida Senior Housing Portfolio (“Central Florida”), the Pinnacle Portfolio (“Pinnacle”), the Bayou Portfolio (“Bayou”) and the Catalina Portfolio (“Catalina”), then adjusting for JLLS’s valuation of the Company’s mortgage loans, term loans, interest rate swap contracts and line of credit payables (the “Debt Liabilities”). The Valuation Report also included the value consideration of two assets that are under contract to be sold by the Company after September 30, 2020 at the contracted sale prices, the Company’s cash, other assets and other liabilities as of September 30, 2020 to calculate an estimated per share NAV of the Company’s common stock.
Upon the Committee’s receipt and review of the Valuation Report, meeting with representatives from JLLS and consideration of the material assumptions and valuation methodologies applied and described therein, the Committee concluded that the range of $8.83 to $9.65 for the updated estimated per share NAV of the Company’s Class T and Class I common stock contained in the Valuation Report was reasonable. The Advisor then recommended that the Committee recommend to the Board $9.22 as the updated estimated per share NAV of the Company’s Class T and Class I common stock, which value is the mid-point of the range of values determined by JLLS in its Valuation Report. Consistent with such recommendation, the Committee recommended to the Board that it adopt $9.22 as the updated estimated per share NAV of the Company’s Class T and Class I common stock. On March 18, 2021, upon the Board’s receipt and review of the Valuation Report, the Board accepted the recommendation of the Committee and approved $9.22 as the updated estimated per share NAV of the Company’s Class T and Class I common stock as of September 30, 2020, exclusive of any portfolio premium.
The table below sets forth the calculation of the Company’s estimated per share NAV as of September 30, 2020 and December 31, 2019. Certain amounts are reflected net of non-controlling interests, as applicable. Year-over-year amounts may not be directly comparable due to in-period acquisitions, capital investments and changes to the Company’s equity base and share count.
Estimated Per Share NAV
| As of September 30, 2020 | As of December 31, 2019 | |||||||||||||||||||||||||
| Estimated Value | Estimated Value Per Share | Estimated Value | Estimated Value Per Share | |||||||||||||||||||||||
| Appraised Properties and Other Properties(1) | $ | 1,203,878,000 | $ | 14.86 | $ | 1,130,167,000 | $ | 14.14 | ||||||||||||||||||
| Cash and Other Assets | 78,112,000 | 0.96 | 77,724,000 | 0.97 | ||||||||||||||||||||||
| Debt Liabilities | (508,612,000) | (6.28) | (421,055,000) | (5.27) | ||||||||||||||||||||||
| Other Liabilities | (24,411,000) | (0.32) | (24,591,000) | (0.30) | ||||||||||||||||||||||
| Advisor Subordinated Participation | — | — | — | — | ||||||||||||||||||||||
| Estimated Net Asset Value | $ | 746,967,000 | $ | 9.22 | $ | 762,245,000 | $ | 9.54 | ||||||||||||||||||
Fully Diluted Shares Outstanding | 80,987,994 | 79,899,874 | ||||||||||||||||||||||||
| _____________ | ||||||||||||||||||||||||||
(1) Appraised Properties net of interest held by the Company’s joint venture partners. Other properties, as of September 30, 2020, includes $7,400,000 of properties that are under contract to be sold by the Company after September 30, 2020 at contracted sale prices.
NAV Methodology and Key Assumptions
In determining an updated estimated per share NAV of the Company’s common stock, the Board considered the recommendation of the Committee, the Valuation Report provided by JLLS and information provided by the Advisor, including third-party reports. The Company’s goal in calculating an estimated per share NAV is to arrive at a value that is reasonable and supportable using what the Committee and the Board each deems to be appropriate valuation methodologies and assumptions.
FINRA’s current rules provide no guidance on the methodology an issuer must use to determine its estimated per share NAV. As with any valuation methodology, the methodologies used are based upon a number of estimates and assumptions that may not be accurate or complete, as well as the necessary valuation assumptions underlying the NAV determination, including discount rates, capitalization rates and interest rates. Different parties with different assumptions and estimates could derive a different estimated per share NAV, and these differences could be significant. The estimated per share NAV is not audited and does not represent the fair value of the Company’s assets less its liabilities according to the United States generally accepted accounting principles (“GAAP”), nor does it represent a liquidation value of the Company’s assets and liabilities or the amount the Company’s shares of common stock would trade at on a national securities exchange. The estimated asset values may not represent current market value or book value. The estimated value of the Appraised Properties does not necessarily represent the value the Company would receive or accept if the assets were marketed for sale. The value of the Company’s shares will fluctuate over time in response to developments related to individual assets in the Company’s portfolio and the management of those assets and in response to the real estate and financial markets, including future developments related to the magnitude and duration of the COVID-19 pandemic and its impact on the Company’s business, its residents, tenants, operators and assets, which are uncertain at this time. The estimated per share NAV does not reflect a discount for the fact that the Company is externally managed, nor does it reflect a real estate portfolio premium/discount compared to the sum of the individual property values. The estimated per share NAV also does not take into account estimated disposition costs and fees for real estate properties or interests therein.
Independent Valuation Firm
JLLS was selected by the Committee to render its Valuation Report as further described below. Jones Lang LaSalle Incorporated (“JLL”) is a New York Stock Exchange-listed, Fortune 500 company with operations in over 80 countries and a leading professional services firm that specializes in real estate and investment management. JLLS, a subsidiary of JLL, is a FINRA registered broker-dealer firm that offers agency leasing, property management, project and development, valuations, capital markets, real estate investment banking and merchant banking, buying and selling properties, and corporate finance services. JLLS and its affiliates possess substantial experience in the valuation of assets similar to those owned by the Company and regularly undertake the valuation of securities in connection with public offerings, private placements, business combinations and similar transactions.
The Company previously engaged CBRE Capital Advisors, Inc. (“CBRE Cap”) as an appraiser to provide its estimate of the per share NAV of the Company’s Class T and Class I common stock calculated as of December 31, 2018 and 2017. The primary personnel that
performed such work on behalf of the Company as of December 31, 2018 and 2017 subsequently departed CBRE Cap and became employed by JLLS. As a result, the Company conducted a competitive process and evaluated the proposals of independent appraisers. After such process and evaluation, the Company engaged JLLS, with approval from the Committee, to deliver its Valuation Report to assist in the estimated per share NAV determination as of September 30, 2020 and December 31, 2019. There is no change with respect to the reliability of the estimates provided by CBRE Cap calculated as of December 31, 2018 and 2017.
While the Company, its affiliates and other entities managed or sponsored by affiliates of the Advisor may have engaged or in the future may engage JLLS or its affiliates for services of various kinds, the Company believes that there are no material conflicts of interest with respect to its engagement of JLLS. For the preparation of the Valuation Report, the Company paid JLLS a customary fee for service of this nature, no part of which was contingent relating to the provision of services or specific findings. In addition, the Company has agreed to indemnify JLLS against certain liabilities arising out of this engagement. With the exception of this current engagement and the aforementioned employees of JLLS who were formerly employed by CBRE Cap, neither JLLS nor its affiliates have been engaged by the Company, the Advisor, or their respective affiliates with respect to valuation services. JLLS or its affiliates may from time to time in the future perform similar or other services for the Company or the Advisor or their respective affiliates. The compensation the Company paid to JLLS related to the valuation is based on the scope of work and not on the appraised values of the Appraised Properties or the estimated per share NAV of the Company.
The appraisal of the Company’s real property assets (“MAI Appraisal”) was performed in accordance with the Code of Ethics and the Uniform Standards of Professional Appraisal Practice, the real estate appraisal industry standards created by The Appraisal Foundation. The MAI Appraisal was commissioned by JLLS from JLL Valuation & Advisory Services. The MAI Appraisal was prepared by personnel who are members of the Appraisal Institute and have the Member of Appraisal Institute (“MAI”) designations. In preparing its Valuation Report, JLLS did not, and was not requested to, solicit third-party indications of interest for the Company’s common stock in connection with possible purchases thereof or the acquisition of all or any part of the Company.
JLLS collected reasonably available material information that it deemed relevant in appraising the Company’s Appraised Properties and Debt Liabilities and estimating the per share NAV of the Company’s common stock. JLLS relied in part on information provided by the Company and the Advisor, including (i) property historical and projected operating revenues, expenses and occupancy; (ii) property lease agreements and/or lease abstracts; (iii) purchase option agreements or summaries; (iv) loan agreements, collateral information and amortization schedules; and (v) information regarding recent or planned capital expenditures. In conducting its investigation and analyses, JLLS took into account customary and accepted financial and commercial procedures and considerations as it deemed relevant. Although JLLS reviewed information supplied or otherwise made available by the Company or the Advisor, it assumed and relied upon the accuracy and completeness of all such information and of all information supplied or otherwise made available to it by any other party and did not independently verify any such information. JLLS has assumed that any operating or financial forecasts and other information and data provided to or otherwise reviewed by or discussed with JLLS were reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments (including subjective judgments) of the Company’s management, the Board and/or the Advisor. JLLS relied on the Company to advise it promptly if any information previously provided became inaccurate or was required to be updated during the period of its review. JLLS assumes no obligation to update or otherwise revise these materials. JLLS and its affiliates are not responsible for the accuracy of the information provided to it by the Company and the Advisor.
Although JLLS considered comments received from the Company or the Advisor during the valuation process, the final appraised values of the Company’s Appraised Properties, including the estimated value of the Company’s joint venture interests and Debt Liabilities in the Valuation Report, were determined by JLLS. The Valuation Report was based upon market, economic, financial and other information, circumstances and conditions existing prior to the Valuation Date, and any material change in such information, circumstances or conditions, may have a material effect on the estimated per share NAV. The Valuation Report is addressed solely to the Committee to assist it in calculating and recommending to the Board an estimated per share NAV of the Company’s common stock. The Valuation Report is not addressed to the public, may not be and should not be relied upon by any other person to establish an estimated per share NAV of the Company’s common stock, and does not constitute a recommendation by JLLS to any person to purchase or sell any shares of the Company’s common stock and should not be represented as such. Neither JLLS nor any of its affiliates, including JLL Valuation & Advisory Services, is responsible for or participated in the Board’s determination of the estimated per share NAV of the Company’s common stock or the price of shares repurchased pursuant to the Company’s SRP.
In performing its analyses, JLLS made numerous assumptions as of various points in time with respect to industry performance, general business, economic and regulatory conditions and other matters, many of which are necessarily subject to change and beyond the control of JLLS and the Company. The analyses performed by JLLS are not necessarily indicative of actual values, trading values or actual future results of the Company’s common stock that might be achieved, all of which may be significantly more or less favorable than suggested by such analyses. JLLS relied on the appraisals and valuations of real properties conducted by JLL Valuation & Advisory Services, and JLLS’s analyses do not purport to be standalone appraisals or to reflect the prices at which the properties may actually be sold, and such estimates are inherently subject to uncertainty. The actual value of the Company’s common stock may vary significantly depending on numerous factors that generally impact the price of securities, the financial condition of the Company
and the state of the real estate industry more generally. Accordingly, with respect to the updated estimated per share NAV of the Company’s common stock, neither the Company nor JLLS can give any assurance that:
•a stockholder would be able to resell his or her shares at the updated estimated per share NAV of the Company;
•a stockholder would ultimately realize distributions per share equal to the updated estimated per share NAV of the Company upon liquidation of the Company’s assets and settlement of the Company’s liabilities or a sale of the Company;
•the Company’s shares would trade at a price equal to or greater than the updated estimated per share NAV of the Company’s common stock if the Company listed them on a national securities exchange;
•a third party would acquire the Company at a value equal to or greater than the updated estimated per share NAV of the Company’s common stock; or
•the methodology used to establish the updated estimated per share NAV of the Company’s common stock would be acceptable to FINRA or under the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for compliance with its reporting requirements.
In addition, the updated estimated per share NAV of the Company’s common stock does not reflect “enterprise value” which may include an adjustment for:
•the large size of the Company’s portfolio given that some buyers may be willing to pay more for a large portfolio than they are willing to pay for each property in the portfolio separately;
•any other intangible value associated with a going concern; or
•the possibility that the Company’s shares could trade at a premium or a discount to net asset value if the Company listed its shares on a national securities exchange.
Furthermore, because the estimated per share NAV is intended to reflect the estimated value on the date that the per share NAV is determined, the updated estimated per share NAV of $9.22 for the Class T common stock does not reflect any obligation to pay future stockholder servicing fees that may potentially become payable after September 30, 2020. As a result, the estimated liability for the payment of future stockholder servicing fees, which was accrued at the time each share was sold, has no effect on the per share NAV for shares of Class T common stock.
The opinions of value expressed in the appraisals prepared by JLL Valuation & Advisory Services are based on estimates and forecasts that are prospective in nature. Due to the COVID-19 pandemic, there is risk and uncertainty in the financial markets. Although JLLS is of the opinion that its findings are reasonable based on available evidence, JLLS is not responsible for the effects of future occurrences that cannot be reasonably foreseen or accurately determined at this time. The COVID-19 pandemic is expected to continue to disrupt financial markets, which may have an impact on the assumptions in the Valuation Report and could negatively impact values, including assumed discount rates, capitalization rates and interest rates. The extent of this impact is unknown at this time.
After review of the range contained in JLLS’s Valuation Report, and in consideration of the factors described above, the Board used an aggregate value of the Appraised Properties and other properties as of September 30, 2020 of approximately $1,203,878,000, to determine the Company’s updated estimated per share NAV, compared with an aggregate initial investment of $1,089,071,000.
The foregoing is a summary of the standard assumptions, qualifications, and limitations that generally apply to the Valuation Report. The Valuation Report, including the analysis, opinions, and conclusions set forth in such report, is qualified by the assumptions, qualifications, and limitations set forth in the report.
Independent Valuation Firm Methodology
Valuation of Appraised Properties
To estimate the value of the Appraised Properties, JLLS conducted an appraisal for the 87 Appraised Properties, consisting of 43 medical office properties and 26 senior housing and skilled nursing properties wholly owned by the Company, as well as 18 senior
housing properties operated utilizing the structure permitted by the REIT Investment Diversification and Empowerment Act of 2007 (“RIDEA”) owned in joint ventures with minority partners.
In preparing the Valuation Report, JLLS, among other things:
•reviewed financial and operating information requested from or provided by the Company and the Advisor;
•reviewed and discussed with senior management of the Company and its Advisor the historical and anticipated future financial performance of the Company’s properties, including forecasts prepared by the Company and the Advisor;
•commissioned the MAI Appraisals and performed analyses and studies for the properties;
•conducted or reviewed JLLS proprietary research, including market and sector capitalization rate surveys;
•reviewed third-party research, including Wall Street equity reports and online data providers;
•compared financial information of the Company to similar information of companies that JLLS deemed to be comparable;
•reviewed the Company’s reports filed with the SEC; and
•reviewed the Company’s unaudited financial statements for the period ended September 30, 2020.
In determining its value opinion of each of the Appraised Properties, JLLS utilized all information that it deemed relevant, including information from the Advisor and its own data sources, including trends in capitalization rates, leasing rates and other economic factors. In conducting its appraisals of the Appraised Properties, and pursuant to its engagement, JLLS utilized an unlevered, ten-year DCF analysis from MAI Appraisals. The terminal capitalization rate method was used to calculate the terminal value of the asset, with such rate based on MAI Appraisals and the specific geographic location of the assets and other relevant factors. In selecting each capitalization rate, JLLS took into account, among other factors, prevailing capitalization rates in the applicable property sector, the property’s location, age and condition, the property’s operating trends and, for net leased properties, the lease coverage ratios, and other unique property factors. In applying the DCF analysis, a market discount rate and terminal capitalization rate was applied to multi-year property projections which factored in, among other things, the leases encumbering the properties, market conditions with respect to lease-up or releasing and property historical and projected operating trends. As applicable, JLLS adjusted the capitalized value of each of the Appraised Properties for any excess land, deferred maintenance or capital needs, rent abatements and lease-up costs to estimate the “as-is” value of each of the Appraised Properties. JLLS then adjusted the “as-is” property values, as appropriate, for the Company’s allocable ownership interest in the Appraised Properties to account for the interests of any third-party investment partners, including any priority distributions. JLLS then applied the terms of the Central Florida, Pinnacle, Bayou and Catalina joint venture agreements, including any distribution priorities and factoring in the value of the promote given to the joint venture partners, to its Central Florida, Pinnacle, Bayou and Catalina equity value estimates to establish the value of the Company’s Central Florida, Pinnacle, Bayou and Catalina interests. JLLS’s Appraisal Report was certified by an appraiser licensed in each state in which the Appraised Properties were located.
After review of the range contained in JLLS’s Valuation Report, and in consideration of the factors described above, the Board used an aggregate estimated value of the Appraised Properties and other properties as of September 30, 2020 of approximately $1,203,878,000, to determine the Company’s updated estimated per share NAV. The following summarizes the key assumptions that were used in the DCF analyses to arrive at the value of the Appraised Properties as of September 30, 2020:
| Assumptions | Range | |||||||
| Discount Rates | ||||||||
Medical Office Buildings | 7.05% - 7.41% | |||||||
| Senior Housing and Skilled Nursing Properties | 8.69% - 9.13% | |||||||
Senior Housing Properties — RIDEA/Partially Owned Properties | 8.02% - 8.43% | |||||||
| Terminal Capitalization Rates | ||||||||
Medical Office Buildings | 6.57% - 6.91% | |||||||
| Senior Housing and Skilled Nursing Properties | 7.94% - 8.35% | |||||||
Senior Housing Properties — RIDEA/Partially Owned Properties | 7.22% - 7.59% | |||||||
Valuation of Debt Liabilities
The estimated value of the Debt Liabilities was determined by JLLS by applying a DCF analysis over the projected remaining term of each debt liability. The cash flows used in the DCF analysis were based on the loan’s contractual agreement and corresponding interest and principal payments. The expected cash flow was then discounted at an interest rate that JLLS deemed appropriate based on what JLLS determined a current market participant, as of September 30, 2020, would require for instruments with similar collateral and duration assuming an orderly market environment, taking into account items such as remaining loan term, loan-to-value ratio, collateral type, debt service coverage, security position, prepayment provisions and other factors deemed relevant, as applicable. The net estimated value was also inclusive of the mark-to-market adjustments for interest rate swap transactions as provided by Chatham Financial Corporation, which discounts future net cash flows based on the London Inter-bank Offered Rate with adjustments for credit risk.
Cash, Other Assets and Other Liabilities
To derive the updated estimated per share NAV, JLLS increased or decreased the estimated value of the Appraised Properties, including the Central Florida, Pinnacle, Bayou and Catalina interests and Debt Liabilities, accordingly, by the Company’s other assets and other liabilities included in the Company’s September 30, 2020 balance sheet. Included in other assets is the Company’s equity investment that is comprised of a 6% interest in a joint venture that owns approximately 97% of Trilogy Investors, LLC (“Trilogy”), the parent company of Trilogy Health Services, LLC, which owns and operates integrated senior health campuses and ancillary businesses. The estimated value of this equity investment was determined based on opinions provided by another third-party valuation firm. Other than an equity investment included in the Company’s other assets, the carrying value of a majority of the Company’s other assets and other liabilities are considered to equal their fair value due to their short maturities or liquid nature. Certain balances, such as operating lease right-of-use assets and lease liabilities, straight-line rent receivables, lease intangible assets and liabilities, deferred financing costs, unamortized lease commissions, and unamortized lease incentives, have been eliminated for the purpose of the valuation due to the fact that the value of those balances were already considered in the valuation of the respective investments or liabilities.
Advisor Subordinated Participation
The updated estimated per share NAV was calculated by JLLS net of the Advisor’s subordinated participation in net sales proceeds in the event of a liquidation of the portfolio, which the Company advised JLLS was equal to 15.0% of net sales proceeds after stockholders are paid a full return of capital plus an annual 6.0% cumulative, non-compounded return. As of September 30, 2020, JLLS attributed no value to the Advisor’s subordinated participation in net sales proceeds in the event of a liquidation of the portfolio.
The Board’s Determination of the Estimated Per Share NAV
On March 17, 2021, JLLS delivered its final Valuation Report to the Committee that contained a range for the Company’s updated estimated per share NAV of $8.83 to $9.65. The Committee was given an opportunity to confer with the Advisor and JLLS regarding the methodologies and assumptions used therein. In consideration of the factors described above, the Advisor recommended that the Committee recommend to the Board $9.22 as the updated estimated per share NAV of the Company’s Class T and Class I common stock. On March 18, 2021, the Committee then recommended that the Board establish $9.22 as the updated estimated per share NAV of the Company’s Class T and Class I common stock, which value is the mid-point of the range of values determined by JLLS. The Board is ultimately and solely responsible for the establishment of the estimated per share NAV of the Company’s Class T and Class I common stock. In arriving at its determination of the updated estimated per share NAV, the Board considered all information provided by JLLS and the Advisor in light of its own familiarity with the Company’s assets and unanimously approved the updated estimated value recommended by the Committee, or an updated estimated per share NAV of the Company’s Class T and Class I common stock of $9.22.
Sensitivity Analysis
Changes to the key assumptions used to arrive at the estimated per share NAV range, including the capitalization rates and discount rates used to value the Appraised Properties, the Central Florida, Pinnacle, Bayou and Catalina interests and Debt Liabilities, could have a significant impact on the underlying value of the Company’s assets. The following table presents the impact on the mid-point of the range of values determined by JLLS resulting from a 2.5% increase and decrease to the discount rates and terminal capitalization rates discussed in the valuation methodology above, which represents a 5.0% sensitivity analysis.
Increase (Decrease) on the Estimated per Share NAV Due to:
| Decrease of 2.5% | Increase of 2.5% | ||||||||||
| Terminal capitalization rate | $ | 0.19 | $ | (0.22) | |||||||
| Discount rate | $ | 0.19 | $ | (0.22) | |||||||
Limitations and Risks of Estimated Per Share NAV
As with any valuation, the methodologies used by the Board to determine the estimated per share NAV are based upon a number of estimates, assumptions, judgments and opinions that may prove later to be inaccurate or incomplete. Further, different market participants using different assumptions and estimates could derive different estimated values.
Although the Board relied on estimated values of the Company’s assets and liabilities in establishing the updated estimated per share NAV, the updated estimated per share NAV may bear no relationship to the Company’s book value as determined by GAAP, as the Company’s book value for most real estate is based on the amortized cost of the property, subject to certain adjustments. In addition, the updated estimated per share NAV may not represent the price at which the shares of the Company’s common stock would trade on a national securities exchange, the amount realized in a sale, merger or liquidation of the Company or the amount a stockholder would realize in a private sale of shares.
Furthermore, in reaching an updated estimated per share NAV of the Company’s shares, the Board did not include a discount for debt that may include a prepayment obligation or a provision precluding assumption of the debt by a third party. In addition, costs that are likely to be incurred in connection with an appropriate exit strategy, whether that strategy involves a listing of the Company’s shares of common stock on a national securities exchange, a merger of the Company or a sale of the Company’s portfolio, were not included in the Board’s updated estimate of the per share NAV of the Company’s shares.
The estimated value of the Company’s assets and liabilities is as of a specific date and such value is expected to fluctuate over time in response to future events, including but not limited to, changes to commercial real estate values, particularly healthcare-related real estate (including, but not limited to, changes to real estate values as a result of the ongoing COVID-19 pandemic), changes in market interest rates for real estate debt, changes in capitalization rates, rental and growth rates, changes in laws or regulations impacting the healthcare industry, demographic changes, returns on competing investments, changes in the amount of distributions on the Company’s common stock, repurchases of the Company’s common stock, the proceeds obtained for any common stock or other transactions, local and national economic factors and the factors specified in Part I, Item 1A, Risk Factors, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and Part II, Item 1A, Risk Factors, of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. There is no assurance that the methodologies used to establish the updated estimated per share NAV would be acceptable to FINRA or in compliance with ERISA guidelines with respect to their reporting requirements.
Forward-Looking Statements
Certain statements contained in this Current Report on Form 8-K, other than historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements include, but are not limited to, statements related to the strategic alternative review process, any consummation of a transaction resulting from the strategic alternative review process, any changes to the Company’s distribution policy, DRIP and SRP, the Company’s expectations regarding the performance of its business, the updated estimated per share NAV of the Company’s common stock, the effects of the COVID-19 pandemic and the Company’s expectations regarding the Company’s future operations and long-term financial prospects. JLLS relied on forward-looking information, some of which was provided by or on behalf of the Company, in preparing its valuation materials. Therefore, neither such statements nor JLLS’s valuation materials are intended to, nor shall they, serve as a guarantee of the Company’s performance in future periods. You can identify these forward-looking statements by the use of words such as “believes,” “expects,” “will,” “should,” “projects,” “intends,” “estimates,” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties, including but not limited to, the following: the Company’s strength and financial condition and uncertainties relating to the financial strength of the Company’s current and future real estate investments and their tenants; uncertainties relating to the Company’s ability to successfully pursue the Company’s strategic plan; uncertainties relating to the local economies where the Company’s real estate investments are located; uncertainties relating to changes in general economic and real estate conditions, including changes as a result of the COVID-19 pandemic; uncertainties regarding changes in the healthcare industry; uncertainties relating to the implementation of the Company’s real estate investment strategy, and those described under the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the SEC. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Current Report on Form 8-K and in the Company’s other filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual events may cause the value and returns on the Company’s investments to be less than that used for purposes of the Company’s updated estimated per share NAV.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Griffin-American Healthcare REIT IV, Inc. | ||||||||
| March 19, 2021 | By: /s/ Jeffrey T. Hanson | |||||||
Name: Jeffrey T. Hanson | ||||||||
Title: Chief Executive Officer | ||||||||
EXHIBIT 99.1
 | 18191 Von Karman Avenue Suite 300 Irvine, CA 92612 (949) 270-9200 | |||||||
March 19, 2021
Dear Fellow Stockholder:
Thank you for your investment in Griffin-American Healthcare REIT IV, Inc. We are writing to provide you with an important company update regarding a strategic alternatives process initiated by our board of directors, as well as to provide you with the results of our annual portfolio valuation and the estimated net asset value (“NAV”) of our shares as determined by our board of directors as of September 30, 2020.
Strategic Alternatives
In October 2020, our board of directors established a special committee comprised of its three independent directors to investigate and analyze, in conjunction with its financial and legal advisors, potential strategic alternatives that may be available to the company in order to maximize shareholder value. Truist Securities is acting as a financial advisor to the Special Committee in the process of reviewing strategic alternatives.
These strategic alternatives could include the sale of the company’s assets, a listing of the company’s shares on a national securities exchange, or a merger with another entity, including a merger with another unlisted entity that we expect would enhance the value of the company.
This is an important process in the life of a non-traded real estate investment trust such as ours, and we are optimistic that the process will lead to enhanced value for you and all of our fellow stockholders. However, it is important to understand that there is no guarantee that this process will lead to the successful completion of any of the options outlined above.
Oftentimes developments in a strategic alternatives review process, such as the one being pursued by the special committee, it becomes prudent to suspend a company’s distribution reinvestment plan (“DRIP”) and share repurchase plan (“SRP”), actions which our management team and board of directors believe are in the best interest of the company and stockholders.
Distribution Reinvestment Plan
Griffin-American Healthcare REIT IV’s DRIP has been suspended effective with distributions declared for the month of April 2021, which are payable in May 2021. All stockholders will continue to receive their full distributions, which will now be paid only in cash as opposed to additional shares of common stock for DRIP participants.
Share Repurchase Plan
While we had previously suspended our SRP with respect to all repurchase requests other than those requests resulting from the death or qualifying disability of stockholders, our SRP is now being suspended for all repurchase requests, and no repurchase requests submitted by stockholders after February 28, 2021 will be fulfilled at this time. Eligible share repurchase requests that were received from stockholders and determined to be in good order prior to February 28, 2021 will be processed in accordance with the terms, conditions and limitations of the SRP.
At this time, we cannot provide any further information regarding the status of the special committee’s evaluation of strategic alternatives, and there is no guarantee that either the DRIP or SRP will be reinstated by our board of directors.
Estimated Net Asset Value Per Share
The most recent valuation of our portfolio was completed as of September 30, 2020 and resulted in the board of directors adopting an updated estimated per share NAV of our Class T and Class I common stock of $9.22. As you will recall, on April 2, 2020, following a valuation of our portfolio as of December 31, 2019, our board of directors determined an estimated per share NAV of our Class T and Class I common stock of $9.54. The updated NAV represents a decline of 3.4 percent compared to our previous NAV, which we believe is a sign of strength given the destructive impact the COVID-19 pandemic has had upon the nation’s economy in general, and upon the healthcare industry in particular.
| www.HealthcareREIT4.com | ||||||||
It is important to note that the estimated per share NAV reported last year was based upon a valuation of our portfolio that took place prior to the onset of the COVID-19 pandemic. As we have cautioned over the course of the past year, the impact of the COVID-19 pandemic on the value of the company’s assets could be significant, as is now reflected in our most recent valuation.
As you know, Griffin-American Healthcare REIT IV invests in quality healthcare-related real estate assets. We purchased our first asset in June 2016 and have since built a diversified portfolio comprised of 94 healthcare properties, as well as an interest in a joint venture which owns a portfolio of integrated senior health campuses and ancillary businesses, acquired for $1.1 billion,1 and which has an estimated value in excess of $1.3 billion.2
Despite the impact of the COVID-19 pandemic on our NAV, we are pleased to report that our portfolio has exhibited significant resiliency and continues to perform relatively well. In fact, many of our assets have increased in value since our prior valuation, but the occupancies, revenue and expenses associated with our senior housing and skilled nursing facilities have been significantly impacted.
We continue to believe that healthcare real estate is among the most compelling investment asset classes available on a risk-adjusted basis and have confidence that our diverse portfolio will continue to weather this challenging crisis. Indeed, we believe the decisive efforts we took early on to preserve cash and strengthen our balance sheet have left us well-positioned to navigate the company through the waning months of the pandemic.
Of course, the estimated per share NAV is simply a snapshot as of a particular date and will fluctuate over time. We remain optimistic about our future prospects — the reality is that the quality of our portfolio, the underlying demographics of the aging United States population and the growing demand for healthcare services have not changed. The impact to our NAV is almost entirely due to what we believe are temporary disruptions wrought by the COVID-19 pandemic and which we are confident will fade over time once it has been brought to heel and the nation returns to a post-pandemic environment.
As you know, the executive officers of Griffin-American Healthcare REIT IV are among the largest individual investors in the company, and we stand shoulder-to-shoulder with you. It has been a difficult year, but as the nationwide vaccination process accelerates and COVID-19 case counts continue to fall, we are confident that the next twelve months will be brighter than the last.
Thank you again for your investment in Griffin-American Healthcare REIT IV and your continued support as we pursue our strategic plan to maximize shareholder value. Should you have any questions, wish to change your address of record or to enroll in automatic electronic deposit of future distributions, please feel free to contact our Investor Services department at (888) 926-2688.
Kind regards,
 |  | ||||
| Jeff Hanson | Danny Prosky | ||||
| Chairman and Chief Executive Officer | President and Chief Operating Officer | ||||
Enclosure
1Based on aggregate contract purchase price of real estate investments acquired as of December 31, 2020, including an interest in a joint venture.
2Based on the gross real estate investments value estimated by the board of directors based in part on a valuation by Jones Lang LaSalle Securities, LLC, an independent Financial Industry Regulatory Authority registered broker-dealer firm that specializes in providing real estate financial services, as of September 30, 2020, including an interest in a joint venture.
| 18191 Von Karman Avenue Suite 300 Irvine, CA 92612 (949) 270-9200 | |||||||
Frequently Asked Questions
1)Why did the board of directors determine an updated estimated per share NAV?
The board of directors determined an updated estimated per share net asset value (“NAV”) of the company’s common stock in order to assist the broker-dealers that participated in our offering in meeting their customer account statement reporting obligations as required by the Financial Industry Regulatory Authority (“FINRA”).
2)Did the valuation include a portfolio premium or other adjustments to value?
The valuation performed by Jones Lang LaSalle Securities, LLC (“JLLS”), an independent FINRA-registered broker-dealer firm that specializes in providing real estate financial services, was conducted pursuant to industry guidelines that do not allow for the consideration of a portfolio premium or other adjustments that we would reasonably expect to accrue in a typical real estate transaction, nor did it include an enterprise value.
3)How was the updated estimated per share NAV determined?
JLLS and/or its affiliates evaluated our property portfolio and calculated an estimated per share range of values of the company’s common stock of $8.83 to $9.65 as of September 30, 2020. The audit committee of the board of directors, comprised solely of independent directors, engaged JLLS and reviewed its valuation analyses and report, and recommended an updated estimated per share NAV to the full board of directors. Based on the audit committee’s recommendation, the board of directors adopted an updated estimated per share NAV of $9.22, which is the mid-point of the range of values provided by JLLS. For a full description of the methodology and assumptions used to determine the updated estimated per share NAV, please see our Current Report on Form 8-K that we filed with the United States Securities and Exchange Commission (the “SEC”) on March 19, 2021.
4)Why did the estimated per share NAV decline?
There are a number of factors that determine the estimated per share NAV of our portfolio. However, it is very clear that the broad economic disruption caused by the global COVID-19 pandemic is the primary cause. As an owner of healthcare real estate, our business, in particular, has experienced significant challenges that have negatively impacted occupancy levels throughout much of our portfolio, resulting in higher costs and reduced revenue. We are confident that the performance of our portfolio, and its estimated value, will rebound as the COVID-19 pandemic wanes.
5)What impact does the updated estimated per share NAV have on the distribution reinvestment plan (“DRIP”)?
The board of directors, in October 2020, formed a special committee comprised of its three independent directors to consider and evaluate, in conjunction with its financial and legal advisors, potential strategic alternatives that may be available to the company to maximize shareholder value, including but not limited to, the sale of the company's assets, a listing of the company's shares on a national securities exchange, or a merger with another entity, including a merger with another unlisted entity that that we expect would enhance the value of the company. In connection with the strategic review process and in order to facilitate a strategic transaction, on March 18, 2021, the DRIP was suspended effective with distributions declared for the month of April 2021, which are payable in May 2021. Distributions will be paid solely in cash until further notice. However, if the DRIP is reinstated, the new purchase price for shares of our Class T and Class I common stock will be equal to the estimated per share NAV in effect at that time
If you are a stockholder who is not currently enrolled in the DRIP (i.e., you receive a monthly cash payment via check or electronic deposit), nothing will change.
For those stockholders who are currently enrolled in the DRIP (i.e., your monthly distribution is currently used to automatically purchase additional shares of stock), you will now receive your monthly distribution in cash per the following guidelines:
•For non-retirement/custodial and non-custodial account holders whose original investment proceeds originated from an established brokerage account, your distributions will be paid directly to that account, provided the account remains open. Should the account be closed and we lack another brokerage account associated with your investment, your monthly cash distribution in the form of a check will be mailed to your address of record currently on file;
| www.HealthcareREIT4.com | ||||||||
•For retirement/custodial account holders, your distribution proceeds will be forwarded to your custodial account and continue to benefit from the qualified tax exemption;
•For non-retirement/non-custodial account holders whose investment proceeds did not originate from a recognizable brokerage account, your monthly cash distribution in the form of a check will be mailed to your address of record currently on file.
We encourage you to consult with your financial advisor should you wish to explore alternate strategies for the payment of your cash distribution.
6)How will the share repurchase plan (“SRP”) change as a result of the updated estimated per share NAV?
In connection with the review of strategic alternatives by the special committee and in order to facilitate a strategic transaction, the company’s SRP has been suspended. No requests for share repurchases submitted after February 28, 2021 will be fulfilled at this time. Eligible share repurchase requests that were received from stockholders and determined to be in good order prior to February 28, 2021 will be processed in accordance with the terms, conditions and limitations of the SRP. Any share repurchase requests received by the company pursuant to the SRP that are not processed due to the suspension shall be considered outstanding share repurchase requests, unless withdrawn by the requesting stockholder.
7)When will the updated estimated per share NAV be reflected on my quarterly customer account statement?
Your quarterly customer account statement will reflect the $9.22 updated estimated per share NAV beginning with your second quarter statement, which will be provided to you in July 2021.
8)Will the estimated per share NAV change?
The board of directors expects to perform annual valuations of our property portfolio henceforth and will adjust the estimated per share NAV accordingly. However, the board of directors may be required to reevaluate the estimated per share NAV sooner depending on any material events that impact the company, its tenants, operators or assets.
9)Who can I contact for additional information?
Please contact our Investor Services department at 888-926-2688 should you have any questions.
This letter contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with respect to the strategic alternative review process; any consummation of a transaction resulting from the strategic alternative review process; any changes to the company’s distribution policy, DRIP and SRP; the updated estimated per share NAV of the company’s common stock and our future determinations thereof; the effects of the COVID-19 pandemic, including its effects on the healthcare industry and senior housing and skilled nursing facilities; the company’s expectations regarding the performance of its business and continued success; and our ability to maximize shareholder value. We intend for all forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act, as applicable by law. Because such statements include risks, uncertainties and contingencies, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties and contingencies include, but are not limited to, the following: our strength and financial condition and uncertainties relating to the financial strength of our current and future real estate investments; uncertainties regarding the severity and duration of the COVID-19 pandemic and its effects; uncertainties relating to our ability to successfully pursue our strategic plan; uncertainties relating to the local economies where our real estate investments are located; uncertainties relating to changes in general economic and real estate conditions; uncertainties regarding changes in the healthcare industry; uncertainties regarding changes in the Institute for Portfolio Alternatives’ practice guideline regarding valuations of publicly registered non-listed real estate investment trusts; uncertainties relating to the implementation of recent healthcare legislation; uncertainties relating to the implementation of our real estate investment strategy; and other risk factors as outlined in the company’s periodic reports, as filed with the SEC. Forward-looking statements in this document speak only as of the date on which such statements were made, and undue reliance should not be placed on such statements. We undertake no obligation to update any such statements that may become untrue because of subsequent events.
Exhibit 99.2
CONSENT OF INDEPENDENT VALUATION EXPERT
Griffin-American Healthcare REIT IV, Inc.
We hereby consent to the reference to our name and description of our role in the valuation process of certain real estate assets of Griffin-American Healthcare REIT IV, Inc. (the “Company”) included in the Current Report on Form 8-K filed on March 19, 2021 and incorporated by reference in the Company’s Registration Statement on Form S-3 (Registration No. 333-229301). In giving this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act of 1933, as amended.
/s/ William J. Cavagnaro
William J. Cavagnaro
President
Jones Lang LaSalle Securities, LLC
Chicago, Illinois
March 19, 2021